CJC-1295

CJC‑1295 is a synthetic analogue of growth hormone‑releasing hormone (GHRH) designed as a long‑acting growth hormone secretagogue for potential use in growth hormone deficiency and related metabolic indications.121314 Early animal and human studies have focused on its ability to produce sustained increases in growth hormone (GH) and insulin‑like growth factor‑1 (IGF‑1) levels.

CJC‑1295 is a 29‑amino‑acid peptide derived from GHRH(1‑29) with substitutions that enhance stability and affinity for serum proteins, particularly when formulated with Drug Affinity Complex (DAC) technology.131412 These modifications extend its half‑life compared with native GHRH, allowing less frequent dosing.

CJC‑1295 binds to GHRH receptors on pituitary somatotrophs, stimulating pulsatile GH release, which secondarily raises circulating IGF‑1.141213 In preclinical models and human volunteers, a single subcutaneous dose produced multi‑day elevations in GH and IGF‑1, suggesting sustained receptor engagement and downstream signaling.1314

In healthy adults, phase 1 data showed dose‑dependent 2‑ to 10‑fold increases in mean GH and 1.5‑ to 3‑fold increases in IGF‑1 for up to 11 days after a single injection, with an estimated half‑life of 5.8–8.1 days.14 Animal work confirms normalization of growth in GHRH‑deficient mice and supports potential applications in growth failure and body composition modulation, though large controlled clinical outcome trials are lacking.1213

• Growth hormone deficiency and related growth disorders121314
• Body composition, including lean mass and fat mass changes in experimental models13
• Sleep architecture and endocrine rhythms with GHRH agonism12
• Anti‑doping detection methods and WADA‑related analytical work12

Human data are largely limited to early‑phase pharmacodynamic and safety studies in small cohorts, without robust long‑term clinical outcome trials.1412 CJC‑1295 is not approved for general therapeutic use and appears on anti‑doping prohibited substance lists, restricting clinical deployment and complicating real‑world data collection.12

1. Teichman SL et al. Prolonged stimulation of growth hormone and IGF‑I by CJC‑1295, a long‑acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006.14
2. MacIntyre I et al. Once‑daily administration of CJC‑1295 normalizes growth in GHRH‑knockout mice. (Preclinical study).13
3. CJC‑1295: Reviews, Clinical Trials, and Safety. Cochrane‑style research overview. 2025.12